Show simple item record

AuthorMestiri, Sarra
AuthorMerhi, Maysaloun
AuthorInchakalody, Varghese P.
AuthorTaib, Nassiba
AuthorSmatti, Maria K.
AuthorAhmad, Fareed
AuthorRaza, Afsheen
AuthorAli, Fatma H.
AuthorHydrose, Shereena
AuthorFernandes, Queenie
AuthorAnsari, Abdul W.
AuthorSahir, Fairooz
AuthorAl-Zaidan, Lobna
AuthorJalis, Munir
AuthorGhoul, Mokhtar
AuthorAllahverdi, Niloofar
AuthorAl Homsi, Mohammed U.
AuthorUddin, Shahab
AuthorJeremijenko, Andrew Martin
AuthorNimir, Mai
AuthorAbu-Raddad, Laith J.
AuthorAbid, Fatma Ben
AuthorZaqout, Ahmed
AuthorAlfheid, Sameer R.
AuthorSaqr, Hassan Mohamed Hassan
AuthorOmrani, Ali S.
AuthorHssain, Ali Ait
AuthorAl Maslamani, Muna
AuthorYassine, Hadi M.
AuthorDermime, Said
Available date2023-03-28T07:18:57Z
Publication Date2023-02-02
Publication NameFrontiers in Immunology
Identifierhttp://dx.doi.org/10.3389/fimmu.2023.1061255
CitationMestiri S, Merhi M, Inchakalody VP, Taib N, Smatti MK, Ahmad F, Raza A, Ali FH, Hydrose S, Fernandes Q, Ansari AW, Sahir F, Al-Zaidan L, Jalis M, Ghoul M, Allahverdi N, Al Homsi MU, Uddin S, Jeremijenko AM, Nimir M, Abu-Raddad LJ, Abid FB, Zaqout A, Alfheid SR, Saqr HMH, Omrani AS, Hssain AA, Al Maslamani M, Yassine HM and Dermime S (2023) Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study. Front. Immunol. 14:1061255. doi: 10.3389/fimmu.2023.1061255
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85148344598&origin=inward
URIhttp://hdl.handle.net/10576/41362
AbstractIntroduction: The BNT162b2 mRNA-based vaccine has shown high efficacy in preventing COVID-19 infection but there are limited data on the types and persistence of the humoral and T cell responses to such a vaccine. Methods: Here, we dissect the vaccine-induced humoral and cellular responses in a cohort of six healthy recipients of two doses of this vaccine. Results and discussion: Overall, there was heterogeneity in the spike-specific humoral and cellular responses among vaccinated individuals. Interestingly, we demonstrated that anti-spike antibody levels detected by a novel simple automated assay (Jess) were strongly correlated (r=0.863, P<0.0001) with neutralizing activity; thus, providing a potential surrogate for neutralizing cell-based assays. The spike-specific T cell response was measured with a newly modified T-spot assay in which the high-homology peptide-sequences cross-reactive with other coronaviruses were removed. This response was induced in 4/6 participants after the first dose, and all six participants after the second dose, and remained detectable in 4/6 participants five months post-vaccination. We have also shown for the first time, that BNT162b2 vaccine enhanced T cell responses also against known human common viruses. In addition, we demonstrated the efficacy of a rapid ex-vivo T cell expansion protocol for spike-specific T cell expansion to be potentially used for adoptive-cell therapy in severe COVID-19, immunocompromised individuals, and other high-risk groups. There was a 9 to 13.7-fold increase in the number of expanded T cells with a significant increase of anti-spike specific response showing higher frequencies of both activation and cytotoxic markers. Interestingly, effector memory T cells were dominant in all four participants’ CD8+ expanded memory T cells; CD4+ T cells were dominated by effector memory in 2/4 participants and by central memory in the remaining two participants. Moreover, we found that high frequencies of CD4+ terminally differentiated memory T cells were associated with a greater reduction of spike-specific activated CD4+ T cells. Finally, we showed that participants who had a CD4+ central memory T cell dominance expressed a high CD69 activation marker in the CD4+ activated T cells.
SponsorThis research was funded by Academic Health System, Medical Research Center, Hamad Medical Corporation, Doha, Qatar, grant number MRC-01-21-113, and the Article Processing Charges was funded by Academic Health System, Medical Research Center, Hamad Medical Corporation, Doha, Qatar. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.
Languageen
PublisherFrontiers Media
SubjectCOVID-19 vaccine
SARS-CoV-2
spike-specific immune responses
spike-specific T cells expansion
surrogate neutralization
TitlePersistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study
TypeArticle
Volume Number14
ESSN1664-3224
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record